Moderna's mRESVIA, The Only Single-Dose Pre-Filled Syringe RSV Vaccine, Approved By FDA For Adults 60 And Older
Portfolio Pulse from Benzinga Newsdesk
Moderna's mRESVIA, the only single-dose pre-filled syringe RSV vaccine, has been approved by the FDA for adults aged 60 and older.
May 31, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's mRESVIA, the only single-dose pre-filled syringe RSV vaccine, has received FDA approval for use in adults aged 60 and older. This approval could significantly boost Moderna's market position and revenue.
The FDA approval of mRESVIA positions Moderna as a key player in the RSV vaccine market, potentially increasing its market share and revenue. The unique single-dose pre-filled syringe format could also attract more users.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100